دورية أكاديمية
أعرض في EDS

Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study.

التفاصيل البيبلوغرافية
العنوان: Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study.
المؤلفون: van Goor IWJM; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands.; Department of Radiation Oncology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands., Schouten TJ; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands., Verburg DN; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands., Besselink MG; Department of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, the Netherlands., Bonsing BA; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands., Bosscha K; Department of Surgery, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Brosens LAA; Department of Pathology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands., Busch OR; Department of Surgery, Amsterdam UMC, location University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, the Netherlands., Cirkel GA; Department of Medical Oncology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & Meander Medical Center Amersfoort, Utrecht, the Netherlands., van Dam RM; Department of Surgery, Maastricht UMC+, Maastricht, the Netherlands., Festen S; Department of Surgery, OLVG, Amsterdam, the Netherlands., Koerkamp BG; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van der Harst E; Department of Surgery, Maasstad Hospital, Rotterdam, the Netherlands., de Hingh IHJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Intven MPW; Department of Radiation Oncology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands., Kazemier G; Cancer Center Amsterdam, the Netherlands.; Department of Surgery, Amsterdam UMC, location Vrije Universiteit, Amsterdam, the Netherlands., Los M; Department of Medical Oncology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands., Meijer GJ; Department of Radiation Oncology, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands., de Meijer VE; Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Nieuwenhuijs VB; Department of Surgery, Isala, Zwolle, the Netherlands., Roos D; Department of Surgery, Renier de Graaf Gasthuis, Delft, the Netherlands., Schreinemakers JMJ; Department of Surgery, Amphia Hospital, Breda, the Netherlands., Stommel MWJ; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Verdonk RC; Department of Gastroenterology, Regional Academic Cancer Center Utrecht, Utrecht, the Netherlands., van Santvoort HC; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands., Daamen LA; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands.; Imaging Division, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands., Molenaar IQ; Department of Surgery, Regional Academic Cancer Center Utrecht, Utrecht University, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht, the Netherlands.
مؤلفون مشاركون: Dutch Pancreatic Cancer Group
المصدر: Annals of surgery [Ann Surg] 2024 Jan 01; Vol. 279 (1), pp. 132-137. Date of Electronic Publication: 2023 Jul 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Pancreatic Neoplasms* , Carcinoma, Pancreatic Ductal*, Humans ; Cohort Studies ; Disease-Free Survival ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies
مستخلص: Objective: To develop a prediction model for long-term (≥5 years) disease-free survival (DFS) after the resection of pancreatic ductal adenocarcinoma (PDAC).
Background: Despite high recurrence rates, ~10% of patients have long-term DFS after PDAC resection. A model to predict long-term DFS may aid individualized prognostication and shared decision-making.
Methods: This nationwide cohort study included all consecutive patients who underwent PDAC resection in the Netherlands (2014-2016). The best-performing prognostic model was selected by Cox-proportional hazard analysis and Akaike's Information Criterion, presented by hazard ratios (HRs) with 95% confidence intervals (CIs). Internal validation was performed, and discrimination and calibration indices were assessed.
Results: In all, 836 patients with a median follow-up of 67 months (interquartile range 51-79) were analyzed. Long-term DFS was seen in 118 patients (14%). Factors predictive of long-term DFS were low preoperative carbohydrate antigen 19-9 (logarithmic; HR 1.21; 95% CI 1.10-1.32), no vascular resection (HR 1.33; 95% CI 1.12-1.58), T1 or T2 tumor stage (HR 1.52; 95% CI 1.14-2.04, and HR 1.17; 95% CI 0.98-1.39, respectively), well/moderate tumor differentiation (HR 1.44; 95% CI 1.22-1.68), absence of perineural and lymphovascular invasion (HR 1.42; 95% CI 1.11-1.81 and HR 1.14; 95% CI 0.96-1.36, respectively), N0 or N1 nodal status (HR 1.92; 95% CI 1.54-2.40, and HR 1.33; 95% CI 1.11-1.60, respectively), R0 resection margin status (HR 1.25; 95% CI 1.07-1.46), no major complications (HR 1.14; 95% CI 0.97-1.35) and adjuvant chemotherapy (HR 1.74; 95% CI 1.47-2.06). Moderate performance (concordance index 0.68) with adequate calibration (slope 0.99) was achieved.
Conclusions: The developed prediction model, readily available at www.pancreascalculator.com, can be used to estimate the probability of long-term DFS after resection of pancreatic ductal adenocarcinoma.
(Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: JAMA. 2013 Oct 9;310(14):1473-81. (PMID: 24104372)
Sci Rep. 2020 Jan 15;10(1):337. (PMID: 31941932)
BMC Med. 2015 Jan 06;13:1. (PMID: 25563062)
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. (PMID: 32105518)
Ann Surg. 2020 Apr;271(4):e102-e104. (PMID: 32084037)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
Sci Rep. 2020 Nov 3;10(1):18951. (PMID: 33144687)
Int J Surg. 2017 Mar;39:169-175. (PMID: 28161529)
N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490)
J Clin Epidemiol. 2006 Oct;59(10):1087-91. (PMID: 16980149)
J Hepatobiliary Pancreat Sci. 2021 Mar;28(3):287-296. (PMID: 32790012)
Ann Surg Oncol. 2021 Dec;28(13):8249-8260. (PMID: 34258720)
Pancreas. 2005 Jul;31(1):69-73. (PMID: 15968250)
Hepatogastroenterology. 2014 Sep;61(134):1756-61. (PMID: 25436375)
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. (PMID: 30608598)
Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739)
Lancet. 2017 Mar 11;389(10073):1011-1024. (PMID: 28129987)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
N Engl J Med. 2004 Mar 18;350(12):1200-10. (PMID: 15028824)
Clin Cancer Res. 2015 Apr 15;21(8):1944-50. (PMID: 25623214)
Ann Surg. 2018 May;267(5):936-945. (PMID: 28338509)
Ann Surg. 2008 Mar;247(3):456-62. (PMID: 18376190)
Eur J Cancer. 2020 Jan;125:83-93. (PMID: 31841792)
Signal Transduct Target Ther. 2021 Jul 5;6(1):249. (PMID: 34219130)
J Am Coll Surg. 2016 Apr;222(4):448-56. (PMID: 26895735)
CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848)
J Clin Epidemiol. 1994 Nov;47(11):1245-51. (PMID: 7722560)
Ann Surg. 2018 Aug;268(2):215-222. (PMID: 29462005)
تواريخ الأحداث: Date Created: 20230714 Date Completed: 20231220 Latest Revision: 20231220
رمز التحديث: 20231220
مُعرف محوري في PubMed: PMC10727199
DOI: 10.1097/SLA.0000000000006004
PMID: 37450706
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000006004